| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000004303 |
| Receipt No. | R000005148 |
| Official scientific title of the study | PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1 |
| Date of disclosure of the study information | 2010/09/30 |
| Last modified on | 2017/04/30 (Ver. 29) |
| Basic information | ||
| Official scientific title of the study | PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1 | |
| Title of the study (Brief title) | PhaseII study of S-1/CDDP therapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1(KSCC1001) | |
| Region |
|
|
| Condition | |||
| Condition | Gastric Cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and the safety of S-1/CDDP therapy for gastric cancer that recurs after adjuvant chemotherapy with S-1. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Progression Free Survival
|
| Key secondary outcomes | Response rate
Disease Control Rate Overall Survival Time to Treatment Failure Safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | S-1 80mg/m2 (day1-21)
CDDP 60mg/m2 i.v. (day8) to be repeated every 5 weeks |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Written informed consent.
2. Appropriate for the study at the physician's assessment. 3. Histologically confirmed gastric adenocarcinoma. 4. Patients who have HER2-nagative cancer confirmed with IHC and/or FISH. (IHC 0 or 1+ or 2+ and FISH negative(HER2/CEP17<2.0)) 5.Treated with S-1 adjuvant chemotherapy after gastrectomy and lymph node dissection and with no residual tumor. 6. S-1 adjuvant chemotherapy continued at least 6 months. 7. No neo-adjuvant therapy. 8. No prior therapy for recurrent gastric cancer. 9. 1)measurable lesion based on the RECIST criterion. 2)evaluable lesion in contrast enhanced CT, etc. 10. ECOG performance status of 0-1. 11. 20 years of age or older. 12. Required baseline laboratory parameters .(within 14 days before registration): WBC >= 3000/mm3 , <12,000/mm3 Neu >= 1,500/mm3 Plt >= 100,000/mm3 Hb >= 9.0g/dl T-Bil <= 2.0mg/dl AST <= 100U/L (in case of hepatic metastatic patients: <= 200U/L) ALT <= 100U/L (in case of hepatic metastatic patients: <= 200U/L) Cre < 1.5mg/dl CCr >= 50mL/min HER2 negative.(IHC 0 or 1+ or 2+ and FISH negative(HER2/CEP17<2.0)) 13. be able to take oral drugs. |
|||
| Key exclusion criteria | 1. Active other malignancies.
2. Prior S-1 plus other anti-cancer drugs combination chemotherapy. 3. Adjuvant chemotherapy other than S-1 mono therapy. 4. Requiring flucytosine, phenytoin, Warfarin Potassium. 5. History of the severe(grade3 or 4) hypersensitivity 6. Co-mobility, such as interstitial lung disease, lung fibrosis, intestinal paralysis, ileus, uncontrolled diabetes, uncontrolled hypertension, heart failure, serious arrhythmia, myocardial infarction, unstable angina, hepatic failure, liver cirrhosis, requiring anticoagulation therapy, requiring steroid drug, and other severe complication. 7. Active infection 8. Infection with hepatitis B or C virus 9. Watery stools or diarrhea 10. Pregnant or lactating woman 11. No birth-control 12. Mental disorder, central nerve disorder. 13. Infection with HIV virus. 14. Not appropriate for the study at the physician's assessment |
|||
| Target sample size | 44 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshihiko Maehara |
| Organization | Graduate School of Medical Sciences, Kyushu University |
| Division name | Department of Surgery and Science |
| Address | 3-1-1, Maidashi, Higashi-Ku, Fukuoka, Japan, 812-8582 |
| TEL | 092-631-2920 |
| kscc2@cres-kyushu.or.jp | |
| Public contact | |
| Name of contact person | KSCC |
| Organization | Clinical Research Support Center Kyushu |
| Division name | KSCC |
| Address | 3-1-1, Maidashi, Higashi-Ku, Fukuoka, Japan, 812-8582 |
| TEL | 092-631-2920 |
| Homepage URL | |
| kscc2@cres-kyushu.or.jp | |
| Sponsor | |
| Institute | Kyushu Study group of Clinical Cancer |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Clinical Research Support Center Kyushu |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 九州大学(福岡県)、国立病院機構九州がんセンター(福岡県) 、公立学校共済組合九州中央病院(福岡県)、済生会福岡総合病院(福岡県)、製鉄記念八幡病院(福岡県) 、国立病院機構福岡東医療センター(福岡県)、社会保険田川病院(福岡県)、社会保険仲原病院(福岡県)、久留米大学(福岡県)、久留米大学医療センター(福岡県) 、社会保険久留米第一病院 (福岡県) 、公立八女総合病院(福岡県) 、大牟田市立病院(福岡県)、宗像医師会病院(福岡県)、福岡市民病院(福岡県) 、福岡大学病院(福岡県) 、福岡歯科大学医科歯科総合病院 (福岡県)、佐世保市立総合病院(長崎県)、長崎大学(長崎県)、健康保険諫早総合病院(長崎県)、長崎百合野病院(長崎県)、済生会熊本病院(熊本県)、熊本大学(熊本県)、健康保険人吉総合病院(熊本県)、健康保険熊本総合病院(熊本県)、熊本地域医療センター(熊本県)、大分県立病院(大分県)、大分赤十字病院(大分県)、国立病院機構大分医療センター(大分県)、国立病院機構別府医療センター(大分県)、国立病院機構都城病院(宮崎県) 、国立病院機構南九州病院(鹿児島県)、今給黎総合病院(鹿児島県) 、鹿児島大学(鹿児島県)、鹿児島共済会南風病院(鹿児島県)、済生会川内病院(鹿児島県)、鹿児島県立薩南病院(鹿児島県)、広島赤十字・原爆病院(広島県)、松山赤十字病院(愛媛県)、神戸市立医療センター中央市民病院(兵庫県)、独立行政法人 労働者健康福祉機構 岡山労災病院(岡山県)、田川市立病院(福岡県)、三木市立三木市民病院(兵庫県)、九州大学病院別府病院(大分県)、伊万里有田共立病院(佐賀県)、広島赤十字・原爆病院(広島県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005148 |